Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.84 |
| ▸ | CDK2 | P24941 | 8/20 | 0.84 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362109 | 0.92 | IGF1R (0.75) | IGF1RCDK2ALKEGFRKCNH2 | |
| SCHEMBL2351237 | 0.92 | IGF1R (1.00) | IGF1RCDK2INSRALKEGFR | |
| SCHEMBL3315325 | 0.92 | IGF1R (0.84) | IGF1RCDK2INSRALK | |
| SCHEMBL3314030 | 0.91 | IGF1R (0.85) | IGF1RCDK2INSRALKEGFR | |
| SCHEMBL2351194 | 0.91 | IGF1R (0.82) | IGF1RCDK2INSRALKEGFR | |
| SCHEMBL3315412 | 0.90 | IGF1R (0.72) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL3344728 | 0.88 | IGF1R (0.83) | IGF1RCDK2INSREGFRKCNH2 | |
| SCHEMBL2347439 | 0.88 | IGF1R (0.80) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL3314176 | 0.87 | IGF1R (1.00) | IGF1RCDK2ALKEGFRKCNH2 | |
| SCHEMBL2347583 | 0.87 | IGF1R (0.76) | IGF1RCDK2INSRALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | claimed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1391/4885CDK2 292/4885INSR 2029/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1560/4885CDK2 89/4885INSR 1726/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | IGF1R 4384/4885CDK2 64/4885INSR 1896/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1560/4885CDK2 89/4885INSR 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.